• Gastrin I (human): Reliable Tool for Advanced GI Assays

  2026-04-30

  This article provides scenario-driven guidance for biomedical researchers using Gastrin I (human) (SKU B5358) in cell-based and organoid assays. We address laboratory challenges in gastrointestinal physiology studies and demonstrate how APExBIO’s high-purity peptide ensures reproducibility and data quality. Protocol recommendations and evidence-based vendor comparisons help you select the right reagent for sensitive, translational research.

• Multi-Omics Mapping of ARID1A-Driven Resistance in Melanoma

  2026-04-30

  This study integrates multi-omics approaches to dissect resistance mechanisms to BRAF/MAPK inhibitors in melanoma, revealing ARID1A-dependent signaling rewiring and immune evasion. Identification of key resistance nodes such as PRKD1, JUN, and NCK1 highlights new avenues for overcoming therapeutic resistance in BRAF-mutant melanoma.

• Bazedoxifene Inhibits IL-6/GP130: Mechanistic Insights for O

  2026-04-29

  This review highlights Bazedoxifene's (BZA) novel role as an inhibitor of the IL-6/GP130 signaling pathway, a key driver of tumor progression and therapy resistance. The findings suggest BZA's potential for cancer therapy and provide a mechanistic rationale for repositioning this FDA-approved SERM in oncology.

• Disulfiram: Dopamine β-Hydroxylase Inhibitor in Cancer Resea

  2026-04-29

  Disulfiram is redefining cancer research by combining dopamine β-hydroxylase inhibition with potent, copper-enhanced proteasome inhibition. This article details workflow optimizations, practical troubleshooting, and assay design strategies to unlock Disulfiram's potential in apoptosis and synthetic lethality studies, especially in APC-deficient cancer models.

• Ginsenoside Rg1: Triterpene Saponin for Neuroprotection Rese

  2026-04-28

  Ginsenoside Rg1 is redefining neuroprotection workflows by targeting neuroimmune disruption, as shown in recent anesthesia-induced models. This triterpene saponin, available from APExBIO, delivers reproducible results in apoptosis and inflammation research with clear performance advantages and rigorously validated protocols.

• Penicillin G Sodium: Applied Workflows and Troubleshooting

  2026-04-28

  Penicillin G Sodium from APExBIO offers superior control over Gram-positive bacterial contamination in experimental models, thanks to its high purity and validated inhibition of bacterial cell wall biosynthesis. This article guides researchers through protocol design, troubleshooting, and the translation of cutting-edge findings into streamlined laboratory practice.

• Technical Guidance for 0.4% Trypan Blue Solution (K1183)

  2026-04-27

  0.4% Trypan Blue Solution addresses the essential need for rapid, direct cell viability measurement and live/dead cell discrimination in cell culture workflows. It is intended for research use only—unsuitable for diagnostic or therapeutic purposes—and offers a stable, ready-to-use azo dye reagent for reproducible cytotoxicity and apoptosis assays. Use is best confined to laboratory research protocols requiring quantitative viability assessment.

• MG-132 (SKU A2585): Data-Driven Solutions for Cell-Based Ass

  2026-04-27

  This article offers an evidence-based, scenario-driven guide for deploying MG-132 (SKU A2585) in cell viability, apoptosis, and cell cycle assays. Grounded in quantitative literature and best practices, it demonstrates how this proteasome inhibitor streamlines workflows and enhances reproducibility for biomedical researchers. Discover why MG-132 from APExBIO stands out for reliability and experimental rigor.

• KPT330 Enhances CRISPR-Cas9 Precision by Modulating Cas9 mRN

  2026-04-26

  The referenced study identifies KPT330, a clinical selective inhibitor of nuclear export (SINE), as an indirect and irreversible inhibitor of CRISPR-Cas9 activity. By interfering specifically with Cas9 mRNA nuclear export, KPT330 improves the specificity of genome and base editing in human cells, offering a new modality for temporal control and reduction of off-target events in genome engineering.

• CX-4945 (Silmitasertib): Applied CK2 Inhibition Workflows in

  2026-04-25

  CX-4945 (Silmitasertib) stands out as a highly selective CK2 inhibitor enabling both cancer and viral replication studies. This article unpacks sophisticated workflows, troubleshooting insights, and the translational impact of recent mechanistic findings—empowering researchers to navigate the intersection of oncology and antiviral research with confidence.

• Targeted SPP1 Inhibition in TAMs Reduces Tumor Burden

  2026-04-24

  This study presents a phenotypic screening approach to identify small molecule inhibitors of SPP1 in tumor-associated macrophages (TAMs), leading to a novel nanoformulation that effectively suppresses SPP1 and reduces tumor size in preclinical models. The findings offer a new therapeutic strategy for modulating the tumor microenvironment and highlight actionable pathways for translational cancer research.

• Antibody-Based Mapping of Pseudouridine in Cellular and Vira

  2026-04-24

  Martinez Campos et al. introduce PA-Ψ-seq, an antibody-based method for transcriptome-wide mapping of pseudouridine (Ψ) residues, revealing unexpected patterns of Ψ incorporation in both human and HIV-1 RNAs. Their findings highlight gaps in our understanding of Ψ biogenesis and its implications for RNA stability and immune evasion.

• BV6 as a Strategic IAP Antagonist: Translational Impact Unlo

  2026-04-23

  BV6, a selective IAP antagonist from APExBIO, is redefining translational apoptosis research. By targeting inhibitor of apoptosis proteins, BV6 enables precise apoptosis induction, sensitization to radio- and chemotherapy, and innovative disease modeling in cancer and endometriosis. This article provides mechanistic depth, protocol guidance, and strategic insight for researchers, referencing both recent preclinical breakthroughs and the expanding competitive landscape.

• Redefining Co-IP Precision: Mechanistic Insight & Strategy

  2026-04-23

  This thought-leadership article explores how advances in recombinant Protein A/G magnetic bead technology—embodied by the Protein A/G Magnetic Co-IP/IP Kit—are transforming the study of protein-protein interactions and antibody purification. Integrating mechanistic insights from Parkinson’s disease research, the piece charts a strategic path for translational scientists seeking reproducibility and sensitivity in co-immunoprecipitation workflows. The discussion bridges validated molecular mechanisms to practical experimental guidance and positions APExBIO’s solution at the vanguard of next-generation translational research tools.

• Substance P (SKU B6620): Technical Guide for CNS & Inflammat

  2026-04-22

  Substance P (SKU B6620) is a high-purity tachykinin neuropeptide designed for research in pain transmission, neuroinflammation, and immune response modulation. This product offers strict solubility and stability characteristics critical for reproducible in vitro and ex vivo workflows. It is not intended for diagnostic or therapeutic use and should not be used outside validated research protocols.

16203 records 1/1081 page Next 12345 下5页 Last page